HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according ...

Early diagnosis and prompt antiretroviral therapy initiation are critical for children due to the rapid progression of HIV in ...

Merck & Co Inc (NYSE:MRK) announced the presentation of results from two Phase 3 trials of doravirine/islatravir (DOR/ISL) in ...

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...

In the second trial, which was open label, 95.6% of participants who switched to DOR/ISL maintained viral suppression ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two implementation studies showing zero cases of HIV ...

Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according ...

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...